Paclitaxel loading in PLGA nanospheres affected the in vitro drug cell accumulation and antiproliferative activity

Luisa Vicari, Teresa Musumeci, Ignazio Giannone, Luana Adamo, Concetta Conticello, Ruggero De Maria, Rosario Pignatello, Giovanni Puglisi, Massimo Gulisano

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: PTX is one of the most widely used drug in oncology due to its high efficacy against solid tumors and several hematological cancers. PTX is administered in a formulation containing 1:1 Cremophor® EL (polyethoxylated castor oil) and ethanol, often responsible for toxic effects. Its encapsulation in colloidal delivery systems would gain an improved targeting to cancer cells, reducing the dose and frequency of administration. Methods: In this paper PTX was loaded in PLGA NS. The activity of PTX-NS was assessed in vitro against thyroid, breast and bladder cancer cell lines in cultures. Cell growth was evaluated by MTS assay, intracellular NS uptake was performed using coumarin-6 labelled NS and the amount of intracellular PTX was measured by HPLC. Results: NS loaded with 3% PTX (w/w) had a mean size <250 nm and a polydispersity index of 0.4 after freeze-drying with 0.5% HP-Cyd as cryoprotector. PTX encapsulation efficiency was 30% and NS showed a prolonged drug release in vitro. An increase of the cytotoxic effect of PTX-NS was observed with respect to free PTX in all cell lines tested. Conclusion: These findings suggest that the greater biological effect of PTX-NS could be due to higher uptake of the drug inside the cells as shown by intracellular NS uptake and cell accumulation studies.

Original languageEnglish
Article number212
JournalBMC Cancer
Volume8
DOIs
Publication statusPublished - Jul 25 2008

Fingerprint

Nanospheres
Paclitaxel
Pharmaceutical Preparations
Cell Line
Neoplasms
Freeze Drying
Poisons
Thyroid Neoplasms
Urinary Bladder Neoplasms
Ethanol
High Pressure Liquid Chromatography
Breast Neoplasms
In Vitro Techniques
polylactic acid-polyglycolic acid copolymer
Growth

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

Paclitaxel loading in PLGA nanospheres affected the in vitro drug cell accumulation and antiproliferative activity. / Vicari, Luisa; Musumeci, Teresa; Giannone, Ignazio; Adamo, Luana; Conticello, Concetta; De Maria, Ruggero; Pignatello, Rosario; Puglisi, Giovanni; Gulisano, Massimo.

In: BMC Cancer, Vol. 8, 212, 25.07.2008.

Research output: Contribution to journalArticle

Vicari, L, Musumeci, T, Giannone, I, Adamo, L, Conticello, C, De Maria, R, Pignatello, R, Puglisi, G & Gulisano, M 2008, 'Paclitaxel loading in PLGA nanospheres affected the in vitro drug cell accumulation and antiproliferative activity', BMC Cancer, vol. 8, 212. https://doi.org/10.1186/1471-2407-8-212
Vicari, Luisa ; Musumeci, Teresa ; Giannone, Ignazio ; Adamo, Luana ; Conticello, Concetta ; De Maria, Ruggero ; Pignatello, Rosario ; Puglisi, Giovanni ; Gulisano, Massimo. / Paclitaxel loading in PLGA nanospheres affected the in vitro drug cell accumulation and antiproliferative activity. In: BMC Cancer. 2008 ; Vol. 8.
@article{48cfe448ceb042a386f9c0604f85132d,
title = "Paclitaxel loading in PLGA nanospheres affected the in vitro drug cell accumulation and antiproliferative activity",
abstract = "Background: PTX is one of the most widely used drug in oncology due to its high efficacy against solid tumors and several hematological cancers. PTX is administered in a formulation containing 1:1 Cremophor{\circledR} EL (polyethoxylated castor oil) and ethanol, often responsible for toxic effects. Its encapsulation in colloidal delivery systems would gain an improved targeting to cancer cells, reducing the dose and frequency of administration. Methods: In this paper PTX was loaded in PLGA NS. The activity of PTX-NS was assessed in vitro against thyroid, breast and bladder cancer cell lines in cultures. Cell growth was evaluated by MTS assay, intracellular NS uptake was performed using coumarin-6 labelled NS and the amount of intracellular PTX was measured by HPLC. Results: NS loaded with 3{\%} PTX (w/w) had a mean size <250 nm and a polydispersity index of 0.4 after freeze-drying with 0.5{\%} HP-Cyd as cryoprotector. PTX encapsulation efficiency was 30{\%} and NS showed a prolonged drug release in vitro. An increase of the cytotoxic effect of PTX-NS was observed with respect to free PTX in all cell lines tested. Conclusion: These findings suggest that the greater biological effect of PTX-NS could be due to higher uptake of the drug inside the cells as shown by intracellular NS uptake and cell accumulation studies.",
author = "Luisa Vicari and Teresa Musumeci and Ignazio Giannone and Luana Adamo and Concetta Conticello and {De Maria}, Ruggero and Rosario Pignatello and Giovanni Puglisi and Massimo Gulisano",
year = "2008",
month = "7",
day = "25",
doi = "10.1186/1471-2407-8-212",
language = "English",
volume = "8",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - Paclitaxel loading in PLGA nanospheres affected the in vitro drug cell accumulation and antiproliferative activity

AU - Vicari, Luisa

AU - Musumeci, Teresa

AU - Giannone, Ignazio

AU - Adamo, Luana

AU - Conticello, Concetta

AU - De Maria, Ruggero

AU - Pignatello, Rosario

AU - Puglisi, Giovanni

AU - Gulisano, Massimo

PY - 2008/7/25

Y1 - 2008/7/25

N2 - Background: PTX is one of the most widely used drug in oncology due to its high efficacy against solid tumors and several hematological cancers. PTX is administered in a formulation containing 1:1 Cremophor® EL (polyethoxylated castor oil) and ethanol, often responsible for toxic effects. Its encapsulation in colloidal delivery systems would gain an improved targeting to cancer cells, reducing the dose and frequency of administration. Methods: In this paper PTX was loaded in PLGA NS. The activity of PTX-NS was assessed in vitro against thyroid, breast and bladder cancer cell lines in cultures. Cell growth was evaluated by MTS assay, intracellular NS uptake was performed using coumarin-6 labelled NS and the amount of intracellular PTX was measured by HPLC. Results: NS loaded with 3% PTX (w/w) had a mean size <250 nm and a polydispersity index of 0.4 after freeze-drying with 0.5% HP-Cyd as cryoprotector. PTX encapsulation efficiency was 30% and NS showed a prolonged drug release in vitro. An increase of the cytotoxic effect of PTX-NS was observed with respect to free PTX in all cell lines tested. Conclusion: These findings suggest that the greater biological effect of PTX-NS could be due to higher uptake of the drug inside the cells as shown by intracellular NS uptake and cell accumulation studies.

AB - Background: PTX is one of the most widely used drug in oncology due to its high efficacy against solid tumors and several hematological cancers. PTX is administered in a formulation containing 1:1 Cremophor® EL (polyethoxylated castor oil) and ethanol, often responsible for toxic effects. Its encapsulation in colloidal delivery systems would gain an improved targeting to cancer cells, reducing the dose and frequency of administration. Methods: In this paper PTX was loaded in PLGA NS. The activity of PTX-NS was assessed in vitro against thyroid, breast and bladder cancer cell lines in cultures. Cell growth was evaluated by MTS assay, intracellular NS uptake was performed using coumarin-6 labelled NS and the amount of intracellular PTX was measured by HPLC. Results: NS loaded with 3% PTX (w/w) had a mean size <250 nm and a polydispersity index of 0.4 after freeze-drying with 0.5% HP-Cyd as cryoprotector. PTX encapsulation efficiency was 30% and NS showed a prolonged drug release in vitro. An increase of the cytotoxic effect of PTX-NS was observed with respect to free PTX in all cell lines tested. Conclusion: These findings suggest that the greater biological effect of PTX-NS could be due to higher uptake of the drug inside the cells as shown by intracellular NS uptake and cell accumulation studies.

UR - http://www.scopus.com/inward/record.url?scp=50549084065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50549084065&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-8-212

DO - 10.1186/1471-2407-8-212

M3 - Article

C2 - 18657273

AN - SCOPUS:50549084065

VL - 8

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 212

ER -